Kasumi Haruta's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025
Question
Kasumi Haruta of UBS asked how Takeda plans to improve R&D productivity amid its ongoing organizational restructuring and headcount reduction. She also sought confirmation on whether Takeda maintains its assumption of ENTYVIO market exclusivity until 2030-2032, considering biosimilar developments.
Answer
Andrew Plump, President of R&D, explained that the restructuring aims to create a rightsized organization focused on its prioritized late-stage pipeline, enhanced by leveraging data, digital, and technology. President and CEO Christophe Weber confirmed there is no change to the ENTYVIO biosimilar entry assumption of 2030-2032, based on current knowledge of competitor development and Takeda's patent defense.